Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life.

Jennifer TjiaJennifer L LundDeborah S MackAttah MbrahYiyang YuanQiaoxi ChenSeun OsundolireCara L McDermott

Published in: Current epidemiology reports (2021)

EOL deprescribing considerations include medication appropriateness in the context of patient goals for care, expected benefit from medication given life expectancy, and heightened potential for medication-related harm as death nears. Additional data are needed on how EOL deprescribing impacts patient quality of life, caregiver burden, and out-of-pocket medication-related costs to patients and caregivers. Investigators should design deprescribing studies with this information in mind.

Keyphrases

healthcare
adverse drug
palliative care
case report
end stage renal disease
newly diagnosed
prognostic factors
risk factors
public health
machine learning
big data
risk assessment
climate change
drug induced